Tag: aav vectors market

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Adeno-Associated Viral Vectors Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for adeno-associated viral vectors has seen a significant expansion in the past years. Its growth is predicted to rise from $2.69 billion in 2024 to $3.17 billion in 2025, registering a compound annual growth rate (CAGR) of 17.9%. This growth in the historical period can be credited to factors such as vaccine creation, an uptick in funding and investments, collaborations between academia and industry, extension of clinical trials, as well as heightened public awareness and advocacy.

What Is the Forecast for the Adeno-Associated Viral Vectors Market Size Through 2029?

The market size for adeno-associated viral vectors is anticipated to witness exponential growth in the upcoming years, reaching a value of $6.08 billion in 2029 with a compound annual growth rate (CAGR) of 17.6%. The projected growth during this forecast period is due to various factors including enhanced therapeutic applications, the rising incidence of genetic and neurological ailments, regulatory authorizations and backing, alongside production cost cuts. Key trends predicted to shape the forecast period encompass advancements in gene therapy, technological innovation, scalable production processes, collaboration and investment initiatives, and technological advancements.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

What are the Key Market Players in Adeno-Associated Viral Vectors Market and How They’re Evolving?

Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

What Are the Primary Growth Drivers in the Adeno-Associated Viral Vectors Market?

The escalating occurrence of genetic disorders is anticipated to boost the expansion of the adeno-associated viral vectors market. Genetic disorders, which are often characterized by DNA irregularities leading to physical or developmental anomalies, are becoming more commonplace. This rise is attributed to advanced diagnostic techniques, increased awareness, climatic factors, genetic drift, and higher reproductive age. Adeno-associated viral vectors, used in gene therapy for genetic disorders, deliver corrective genes into cells to potentially address conditions such as muscular dystrophy or cystic fibrosis. As per the World Health Organization (WHO), a Switzerland-based United Nations specialized agency for international public health, congenital diseases were responsible for roughly 240,000 neonatal deaths globally inside 28 days of birth annually, as reported in February 2023. Furthermore, congenital diseases contribute to the death of an additional 170,000 children aged between one month and five years. As such, the intensifying occurrence of genetic disorders is propelling the adeno-associated viral vectors market upwards.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp

What Are the Leading Segments in the Global Adeno-Associated Viral Vectors Industry?

The adeno-associated viral vectors market covered in this report is segmented –

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies

2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas

4) By Scale Of Operation: Preclinical, Clinical, Commercial

5) By Application Area: Gene Therapy, Cell Therapy, Vaccines

Subsegments:

1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia

2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy, Autoimmune Diseases Immunotherapy

3) By Other Types Of Therapies: Gene Editing, RNA Therapy, Antiviral Therapy

What Are the Key Market Trends in the Adeno-Associated Viral Vectors Industry?

Top businesses within the adeno-associated viral vectors marketplace are prioritizing the provision of readily available replication-capsid plasmid to create a competitive advantage. Rep/Cap plasmids, frequently used in adeno-associated virus (AAV) vector production for gene therapy, can be easily procured from a wide array of commercial vendors that cater to molecular biology research requirements. For instance, in January 2024, the US pharmaceutical firm, Charles River Laboratories International Inc., unveiled a range of off-the-shelf replication-capsid plasmid, which simplifies AAV-based gene therapy schemes. This addition to their product line pairs well with their existing lentiviral packaging and AAV Helper plasmid products, reducing manufacturing efforts by nearly 66%. These ready-for-use plasmids are produced in batches with careful documentation, complying with CMC regulations and accompanied by a Certificate of Analysis (COA), making it easier for IND and Clinical Trial Application (CTA) submissions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

What Is the Regional Outlook for the Adeno-Associated Viral Vectors Market?

North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15969

This Report Delivers Insight On:

1. How big is the adeno-associated viral vectors market, and how is it changing globally?

2. Who are the major companies in the adeno-associated viral vectors market, and how are they performing?

3. What are the key opportunities and risks in the adeno-associated viral vectors market right now?

4. Which products or customer segments are growing the most in the adeno-associated viral vectors market?

5. What factors are helping or slowing down the growth of the adeno-associated viral vectors market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the adeno-associated viral vectors industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Is the Estimated Market Size of the Adeno-Associated Viral Vectors Market In 2029?#_x000D_

The market size for adeno-associated viral vectors has experienced swift expansion in the past few years. The market is projected to increase from $2.69 billion in 2024 to $3.17 billion in 2025, showcasing a compound annual growth rate (CAGR) of 17.9%. Factors like vaccine formulation, heightened financing and investment, partnerships between academia and industry, broadening of clinical trials, as well as improved public consciousness and advocacy have been instrumental in driving growth during the historical period._x000D_

_x000D_

In the ensuing years, a swift expansion is projected for the adeno-associated viral vectors market, with its size likely to reach $6.08 billion in 2029, thanks to a compound annual growth rate (CAGR) of 17.6%. The expansion during the prediction period is attributed to factors such as broader therapeutic applications, a surge in genetic and neurological disorders, regulatory endorsements and backing, and decrease in production costs. The forecast period will also witness various trends such as progress in gene therapy, technological breakthroughs, mass scale manufacturing methods, partnerships and investments, and additional technological advancements._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp_x000D_

_x000D_

#Which Factors and External Forces Are Driving Demand in the Adeno-Associated Viral Vectors Market?#_x000D_

The escalating rate of genetic disorders is predicted to drive the expansion of the adeno-associated viral vectors market. Genetic disorders, which result from anomalies in a person’s DNA and cause physical or developmental discrepancies, are on the rise due to advancements in diagnostic techniques, heightened awareness, increasing reproductive age as well as environmental influences and genetic drift. Adeno-associated viral vectors play a crucial role in gene therapy for genetic disorders as they insert corrective genes into designated cells; this might potentially treat diseases such as muscular dystrophy or cystic fibrosis. In February 2023, the World Health Organization (WHO), a Switzerland-based specialized wing of the United Nations dedicated to global public health, stated that congenital defects are responsible for approximately 240,000 neonatal deaths worldwide within a month of birth each year. Moreover, congenital diseases also account for the death of an additional 170,000 children aged between 1 month and 5 years. Consequently, the rising incidence of genetic disorders is fuelling the adeno-associated viral vectors market._x000D_

_x000D_

#Which Segments in the Adeno-Associated Viral Vectors Offer the Most Growth?#_x000D_

The adeno-associated viral vectors market covered in this report is segmented –_x000D_

_x000D_

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies_x000D_

2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo_x000D_

3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas_x000D_

4) By Scale Of Operation: Preclinical, Clinical, Commercial_x000D_

5) By Application Area: Gene Therapy, Cell Therapy, Vaccines_x000D_

_x000D_

Subsegments:_x000D_

1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia_x000D_

2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy, Autoimmune Diseases Immunotherapy_x000D_

3) By Other Types Of Therapies: Gene Editing, RNA Therapy, Antiviral Therapy_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the Adeno-Associated Viral Vectors Market?#_x000D_

North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Cutting-Edge Market Trends Are Expected to Drive the Adeno-Associated Viral Vectors Market’s Growth?#_x000D_

Leading entities in the adeno-associated viral vectors market are shifting their attention to providing ready-to-use replication-capsid plasmid to gain a superior market position. Rep/Cap plasmids, which are commonly employed in AAV vector production for gene therapy, are easily accessible from a variety of vendors who meet the needs of molecular biology research. For example, Charles River Laboratories International Inc., an American pharmaceutical company, debuted a range of off-the-shelf replication-capsid plasmids in January 2024. These plasmids streamline AAV-based gene therapy projects and augment existing lentiviral packaging and AAV Helper plasmid lines – reducing manufacturing work by as much as two-thirds. These ready-for-use plasmids are produced in batches, with thorough documentation, in accordance with CMC guidelines. They also come with a Certification of Analysis (COA) to aid IND and Clinical Trial Application (CTA) processes._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the Adeno-Associated Viral Vectors Market?#_x000D_

Adeno-associated viral vectors (AAV) are small, non-pathogenic viruses commonly used in gene therapy. They are engineered to deliver therapeutic genes into target cells, offering potential treatments for genetic disorders, cancers, and other diseases. AAV’s safety profile and ability to efficiently infect both dividing and non-dividing cells make them valuable tools in biomedical research and clinical applications._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15969_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theAdeno-Associated Viral Vectors Market?

The adeno-associated viral vectors market is anticipated to expand due to the growing occurrence of genetic disorders. Genetic disorders manifest as physical or developmental abnormalities resulting from DNA aberrations in a person. The rise in genetic disorder cases is attributed to enhanced diagnostic methods, heightened awareness, increased reproductive age, environmental factors, and genetic drift. Adeno-associated viral vectors play a crucial role in the gene therapy of genetic disorders, as they transport corrective genes into the target cells, potentially offering treatments for ailments such as muscular dystrophy or cystic fibrosis. As per the World Health Organization (WHO) in February 2023, congenital diseases resulted in about 240,000 neonate fatalities worldwide within the first 28 days of birth annually. Congenital diseases are also responsible for an additional 170,000 deaths annually among children aged from 1 month to 5 years. Thus, the escalating incidence of genetic disorders is propelling the adeno-associated viral vectors market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

How Will the Growth Rate of theAdeno-Associated Viral Vectors Market Impact Industry Trends by 2034?

The market size for adeno-associated viral vectors has experienced swift growth in the past few years. Projections indicate that it will expand from $2.69 billion in 2024 up to $3.17 billion in 2025, with a compound annual growth rate (CAGR) of 17.9%. The surge seen in the preceding era can be linked to factors such as vaccine creation, amplified funding and investments, collaborations between academics and industry, enlargement of clinical trials, and heightened public awareness and advocacy.

In the upcoming years, the adeno-associated viral vectors market is predicted to witness fast-paced expansion and is estimated to reach $6.08 billion in 2029, with a compound annual growth rate (CAGR) of 17.6%. The growth during this forecast period is expected to be driven by factors such as the increase of therapeutic uses, the rise of genetic and neurological disorders, regulatory endorsements and aid, along with the reduction of production expenses. Principal trends that will influence this market in the estimated period comprise advances in gene therapy, technological breakthroughs, replicable manufacturing methods, cooperation and investments, and further technological development.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15969

Which Cutting-Edge Market Trends Are Expected to Drive theAdeno-Associated Viral Vectors Market’s Growth?

Key players in the adeno-associated viral vectors market, like Charles River Laboratories International Inc., are striving to gain a market advantage by ensuring the off-the-shelf availability of replication-capsid plasmid. Rep/Cap plasmids, frequently used in AAV vector production for gene therapy, are conveniently available from a host of commercial sources meeting molecular biology research demands. As an example, in January 2024, the American pharmaceutical firm Charles River Laboratories broadened their product range by introducing off-the-shelf replication-capsid plasmid to boost AAV-based gene therapy endeavors. This new addition aligns well with their current lentiviral packaging and AAV Helper plasmid offerings, reducing manufacturing workload by up to 66%. These ready-for-use plasmids are produced in batches, with rigorous documentation in line with CMC regulations, and they come with a Certificate of Analysis (COA) to aid IND and CTA submissions.

What Are the Leading Market Players Impacting theAdeno-Associated Viral Vectors Market’s Growth Trend?

Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

How Are the Key Segments of the Adeno-Associated Viral Vectors Market Driving Opportunities and Innovations?

The adeno-associated viral vectors market covered in this report is segmented –

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies

2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas

4) By Scale Of Operation: Preclinical, Clinical, Commercial

5) By Application Area: Gene Therapy, Cell Therapy, Vaccines

Subsegments:

1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia

2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy, Autoimmune Diseases Immunotherapy

3) By Other Types Of Therapies: Gene Editing, RNA Therapy, Antiviral Therapy

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theAdeno-Associated Viral Vectors Market?# Market Expansion?

North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Adeno-Associated Viral Vectors Market 2025, By The Business Research Company:

The Antiviral & Antimicrobial Coatings Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Viral Vectors And Plasmid DNA Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the adeno-associated viral vectors market size evolved in recent years?

The adeno-associated viral vectors market is forecast to grow from $2.69 billion in 2024 to $3.17 billion in 2025, at a CAGR of 17.9%. Growth is fueled by vaccine development, increased funding, academic and industrial collaborations, the expansion of clinical trials, and heightened public awareness and advocacy.

What are the predictions for the adeno-associated viral vectors market size in the coming years?

The adeno-associated viral vectors market is projected to grow to $6.08 billion by 2029, at a CAGR of 17.6%. Growth is driven by expanding therapeutic applications, the rise in genetic and neurological disorders, regulatory approvals, and cost reductions in production. Major trends include advancements in gene therapy, scalable manufacturing, and investments in technological innovations.

Get your adeno-associated viral vectors market report here!

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

What key factors are fueling the growth of the adeno-associated viral vectors market?

The increasing prevalence of genetic disorders is expected to drive the adeno-associated viral vectors market. Genetic disorders, caused by abnormalities in DNA, are becoming more common due to better diagnostics and higher reproductive age. Adeno-associated viral vectors are used in gene therapy to treat genetic disorders by delivering corrective genes to targeted cells. For example, the World Health Organization estimated that 240,000 infant deaths each year are caused by congenital diseases. This rise in genetic disorders is expected to drive the demand for adeno-associated viral vectors.

How is the global adeno-associated viral vectors market divided into key segments?

The adeno-associated viral vectors market covered in this report is segmented –

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies

2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas

4) By Scale Of Operation: Preclinical, Clinical, Commercial

5) By Application Area: Gene Therapy, Cell Therapy, Vaccines

Subsegments:

1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia

2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy, Autoimmune Diseases Immunotherapy

3) By Other Types Of Therapies: Gene Editing, RNA Therapy, Antiviral Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

Who are the key firms paving the way for growth in the adeno-associated viral vectors market?

Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

Which trends are expected to transform the adeno-associated viral vectors market?

Companies in the adeno-associated viral vectors market are offering off-the-shelf replication-capsid plasmids to streamline gene therapy production. These plasmids are essential in the creation of AAV vectors for gene therapies. For example, in January 2024, Charles River Laboratories launched a new line of off-the-shelf replication-capsid plasmids that simplify AAV-based gene therapy processes. These ready-to-use plasmids cut manufacturing efforts and adhere to regulatory guidelines, ensuring smooth IND and CTA submissions.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15969

What regions are contributing significantly to the growth of the adeno-associated viral vectors market?

North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

The Antiviral & Antimicrobial Coatings Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Viral Vectors And Plasmid DNA Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Expected Growth Rate of the Adeno-Associated Viral Vectors Market Based on Industry Projections?

The market size for adeno-associated viral vectors has seen extensive growth in recent years. The market, valued at $2.69 billion in 2024, is predicted to expand to $3.17 billion in 2025 with a compound annual growth rate (CAGR) of 17.9%. Factors contributing to historical growth include vaccine development, increased capital investment, partnerships between academia and industry, the proliferation of clinical trials, as well as raised public consciousness and advocacy.

The market for adeno-associated viral vectors is predicted to undergo swift expansion in the forthcoming years. It is projected to escalate to $6.08 billion by 2029, with a compound annual growth rate (CAGR) of 17.6%. The predicted rise during the forecast timeframe could be due to factors such as the widening scope of therapeutic applications, a higher occurrence rate of genetic and neurological disorders, regulatory endorsement and aid, and the slashing down of production costs. The major trends expected to shape this market in the forecast period are progress in gene therapy, technological breakthroughs, the ability to scale manufacturing processes, partnerships and financial investments, as well as advancements in technology.

What Are the Primary Drivers Supporting the Growth of the Adeno-Associated Viral Vectors Market?

The growth of the adeno-associated viral vectors market is expected to be fueled by the rising incidence of genetic disorders. Genetic disorders, conditions that result from DNA abnormalities leading to physical or developmental anomalies, are on the rise due to improved diagnostic methods, increased awareness, older reproductive age, along with environmental factors and genetic drift. Adeno-associated viral vectors play a crucial role in gene therapy for these genetic disorders by delivering the necessary genes into target cells, potentially treating conditions such as muscular dystrophy or cystic fibrosis. For example, the World Health Organization (WHO), the United Nations’ Switzerland-based agency responsible for global public health, reported in February 2023 that congenital diseases cause approximately 240,000 infant deaths worldwide within 28 days of birth each year. There is an additional death toll of 170,000 children aged between 1 month and 5 years from congenital diseases. Hence, the rising prevalence of genetic disorders is fueling the growth of the adeno-associated viral vectors market.

Explore Comprehensive Insights Into The Global Adeno-Associated Viral Vectors Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

What Companies Are At the Forefront of Innovation in the Adeno-Associated Viral Vectors Market?

Major companies operating in the adeno-associated viral vectors market are:

• Pfizer Inc.

• Astellas Pharma

• Biogen Inc.

• Charles River Laboratories International Inc.

• BioMarin Pharmaceutical Inc.

How Are Emerging Trends in Consumer Behavior Affecting the Adeno-Associated Viral Vectors Market?

In order to gain a competitive advantage in the adeno-associated viral vectors market, key players are striving to offer instant availability of replication-capsid plasmid. This product is frequently used in gene therapy for the production of the adeno-associated virus (AAV) vector and can be obtained from a variety of commercial sources that serve the needs of molecular biology research. For example, in January 2024, Charles River Laboratories International Inc., a pharmaceutical firm based in the United States, launched a range of ready-to-use replication-capsid plasmids that simplify AAV-based gene therapy efforts. This new addition to their product line not only complements their existing lentiviral packaging and AAV Helper plasmid offerings but also reduces manufacturing efforts by up to 66%. These plasmids are produced in batches, following rigorous documentation processes, conforming to CMC guidelines, and issued with a Certification of Analysis (COA) to aid IND and Clinical Trial Application (CTA) submissions.

Secure Your Global Adeno-Associated Viral Vectors Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Which Key Segments Define the Structure of the Adeno-Associated Viral Vectors Market and Their Growth Potential?

The adeno-associated viral vectors market covered in this report is segmented –

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies

2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas

4) By Scale Of Operation: Preclinical, Clinical, Commercial

5) By Application Area: Gene Therapy, Cell Therapy, Vaccines

Subsegments:

1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia

2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy, Autoimmune Diseases Immunotherapy

3) By Other Types Of Therapies: Gene Editing, RNA Therapy, Antiviral Therapy

What Regions Are Propelling Growth in the Adeno-Associated Viral Vectors Industry?

North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does the Definition of the Adeno-Associated Viral Vectors Market Include?

Adeno-associated viral vectors (AAV) are small, non-pathogenic viruses commonly used in gene therapy. They are engineered to deliver therapeutic genes into target cells, offering potential treatments for genetic disorders, cancers, and other diseases. AAV’s safety profile and ability to efficiently infect both dividing and non-dividing cells make them valuable tools in biomedical research and clinical applications.

Browse Through More Similar Reports By The Business Research Company:

The Antiviral & Antimicrobial Coatings Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Viral Vectors And Plasmid DNA Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: